Streptococcus pneumoniae infection primary prevention: Difference between revisions
(Created page with "{{Streptococcus pneumoniae}} {{CMG}} ==Overview== ==References== {{reflist|2}} Category:Disease Category:Infectious disease Category:Pulmonology {{WH}} {{WS}}") |
|||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
==Vaccination in the USA== | |||
In the USA, a heptavalent pneumococcal [[conjugate vaccine]] vaccine (PCV 7) (e.g. [[Prevnar]]) is recommended since 2000 for all children aged 2-23 months and for at-risk children aged 24-59 months. The normally 4-doses series is given at 2, 4, 6 & 12 - 14 months of age. Protection is good against deep pneumococcal infections (especially septicemia and meningitis). Similar 9- and 13-valent vaccines are being tested. Yet, if the child is exposed to a serotype of pneumococcus that is not contained in the vaccine, he/she is not afforded any protection. This limitation, and the ability of capsular-polysaccharide conjugate vaccines to promote the spread of non-covered serotypes, has led to research into vaccines that would provide species-wide protection. | |||
[[Pneumococcal polysaccharide vaccine]] (Pneumovax™ is one brand) gives at least 85% protection in those under 55 years of age for five years or longer. Immunization is suggested for those at highest risk of infection, including those 65 years or older, and generally should be a single lifetime dose (high risk side effects if repeated). The standard 23-valent vaccines are ineffective for children under two years old. | |||
The current guidelines of the [[American College of Physicians]] call for administration of the immunization between ages 2 and 65 when indicated, or at age 65. If someone received the immunization before age 60, the guidelines call for a one-time revaccination. | |||
''Revaccination'' at periodic intervals is also indicated for those with other conditions such as [[asplenia]] or [[nephrotic syndrome]]. | |||
==Vaccination in the UK== | |||
It was announced in February 2006 that the UK government would introduce vaccination with the conjugate vaccine in children aged 2, 4 and 13 months.<ref name="BBCVac">[http://news.bbc.co.uk/1/hi/health/4692908.stm "Children to be given new vaccine"] ''BBC News'', [[February 08]], [[2006]], retrieved [[August 25]], [[2006]]</ref><ref name="DoHPress">[http://www.dh.gov.uk/PublicationsAndStatistics/PressReleases/PressReleasesNotices/fs/en?CONTENT_ID=4128036&chk=PI8e57 "Pneumococcal vaccine added to the childhood immunisation programme"] [[February 08]], [[2006]]</ref> This is expected to start on [[September 4]],[[2006]] and is to include changes to the immunisation programme in general.<ref name="MRF">[http://www.meningitis.org/sect5/subsect12/page1 "Changes to the immunisation programme in the UK"] ''Meningitis Research Foundation'', retrieved [[August 25]], [[2006]]</ref> | |||
==Vaccination Worldwide== | |||
[[PneumoADIP|Pneumococcal vaccines Accelerated Development and Introduction Plan (PnemoADIP)]] is a program to accelerate the evaluation and access to new pneumococcal vaccines in the developing world. PneumoADIP is funded by the [[Global Alliance for Vaccines and Immunization|Global Alliance for Vaccines and Immunization (GAVI)]]. Thirty GAVI countries have expressed interest in participating by 2010. PneumoADIP aims to save 5.4 million children by 2030.<ref name="PneumoADIP website">[http://www.pneumoadip.com "PneumoADIP website"]</ref> | |||
==References== | ==References== | ||
Revision as of 17:42, 2 February 2012
Template:Streptococcus pneumoniae Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Vaccination in the USA
In the USA, a heptavalent pneumococcal conjugate vaccine vaccine (PCV 7) (e.g. Prevnar) is recommended since 2000 for all children aged 2-23 months and for at-risk children aged 24-59 months. The normally 4-doses series is given at 2, 4, 6 & 12 - 14 months of age. Protection is good against deep pneumococcal infections (especially septicemia and meningitis). Similar 9- and 13-valent vaccines are being tested. Yet, if the child is exposed to a serotype of pneumococcus that is not contained in the vaccine, he/she is not afforded any protection. This limitation, and the ability of capsular-polysaccharide conjugate vaccines to promote the spread of non-covered serotypes, has led to research into vaccines that would provide species-wide protection.
Pneumococcal polysaccharide vaccine (Pneumovax™ is one brand) gives at least 85% protection in those under 55 years of age for five years or longer. Immunization is suggested for those at highest risk of infection, including those 65 years or older, and generally should be a single lifetime dose (high risk side effects if repeated). The standard 23-valent vaccines are ineffective for children under two years old.
The current guidelines of the American College of Physicians call for administration of the immunization between ages 2 and 65 when indicated, or at age 65. If someone received the immunization before age 60, the guidelines call for a one-time revaccination.
Revaccination at periodic intervals is also indicated for those with other conditions such as asplenia or nephrotic syndrome.
Vaccination in the UK
It was announced in February 2006 that the UK government would introduce vaccination with the conjugate vaccine in children aged 2, 4 and 13 months.[1][2] This is expected to start on September 4,2006 and is to include changes to the immunisation programme in general.[3]
Vaccination Worldwide
Pneumococcal vaccines Accelerated Development and Introduction Plan (PnemoADIP) is a program to accelerate the evaluation and access to new pneumococcal vaccines in the developing world. PneumoADIP is funded by the Global Alliance for Vaccines and Immunization (GAVI). Thirty GAVI countries have expressed interest in participating by 2010. PneumoADIP aims to save 5.4 million children by 2030.[4]
References
- ↑ "Children to be given new vaccine" BBC News, February 08, 2006, retrieved August 25, 2006
- ↑ "Pneumococcal vaccine added to the childhood immunisation programme" February 08, 2006
- ↑ "Changes to the immunisation programme in the UK" Meningitis Research Foundation, retrieved August 25, 2006
- ↑ "PneumoADIP website"